Accelerate Diagnostics 2023 Company Presentation

Accelerate Diagnostics presented its Accelerate Pheno® rapid AST platform, the first FDA-approved rapid antimicrobial susceptibility testing system with strong clinical impact. The company outlined commercialization plans for Wave™ and Arc™ platforms targeting a $2B AST market, with expected clinical trials in Q2 2024 and FDA submission in Q3 2024, alongside a commercial partnership with Becton Dickinson.